dacarbazine - Robuta Search

https://www.mayoclinic.org/drugs-supplements/dacarbazine-intravenous-route-injection-route/description/drg-20063285 Dacarbazine (intravenous route, injection route) - Side effects & dosage - Mayo Clinic side effects dacarbazine intravenous route injection https://pmc.ncbi.nlm.nih.gov/articles/PMC8758066/ Spectrometric Results of Process Variations in Dacarbazine - PMC Intra-lot and inter-lot variability in dacarbazine was detected in the Drug Quality Study (DQS) using Fourier transform near-infrared spectrometry (FTNIR). One... results process variations dacarbazine pmc https://www.cancer.gov/about-cancer/treatment/drugs/dacarbazine?cid=eb_govdel Dacarbazine - NCI This page contains brief information about dacarbazine and a collection of links to more information about the use of this drug, research results, and ongoing... dacarbazine nci https://bibliographie.uni-tuebingen.de/xmlui/handle/10900/80253 Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a... in patients https://pubchem.ncbi.nlm.nih.gov/patent/EP-0288055-B1 Use of odc inhibitors, dacarbazine, and interferon, in the treatment of malignant melanoma - Patent... EP-0288055-B1 chemical patent summary. https://adisinsight.springer.com/drugsafety/803270617?error=cookies_not_supported&code=3777723d-0708-445e-8dd5-9b331cc7e7d8 Dacarbazine/pembrolizumab - AdisInsight A 42-year-old man developed bullous pemphigoid like drug eruption during therapy with pembrolizumab and fatigue with dryness of skin during therapy with dacarbazine pembrolizumab adisinsight https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-cnto-95-with-or-without-dacarbazine-for-advanced-melanoma A trial looking at intetumumab, with or without dacarbazine (DTIC), for advanced melanoma This trial looked at intetumumab (also called CNTO 95), with or without dacarbazine (DTIC), for advanced melanoma skin cancer. https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-eribulin-dacarbazine-sarcoma A trial looking at eribulin and dacarbazine for sarcoma This trial compared the chemotherapy drugs eribulin and dacarbazine for people with soft tissue sarcoma that had come back after treatment. looking at trial dacarbazine sarcoma https://adisinsight.springer.com/drugsafety/803115022?error=cookies_not_supported&code=a6d6409a-a6bc-443c-9431-3f0ea5669987 Bleomycin/dacarbazine/doxorubicin/vinblastine - AdisInsight A woman in her 60's was diagnosed with peripheral T cell lymphoma (TCL) after 2 years of chemotherapy with bleomycin, dacarbazine, doxorubicin and bleomycin dacarbazine doxorubicin vinblastine adisinsight https://pubmed.ncbi.nlm.nih.gov/20445347/ Anti-melanoma activity of the 9.2.27PE immunotoxin in dacarbazine resistant cells We have earlier shown that the 9.2.27 Pseudomonas Exotoxin A (PE) immunotoxin (IT) efficiently kills melanoma cells through inhibition of protein synthesis... https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-azd6244-and-dacarbazine-advanced-melanoma-people-with-braf-gene-fault A trial of selumetinib with dacarbazine for advanced melanoma in people with a BRAF gene fault This trial looked at a drug called selumetinib alongside dacarbazine for people with melanoma that has spread to another part of the body. https://experts.arizona.edu/en/publications/a-phase-1-2-study-of-imexon-plus-dacarbazine-in-patients-with-unr/ A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma -... https://www.cancerresearchuk.org/about-cancer/treatment/drugs/dacarbazine Dacarbazine (DTIC) | Cancer information | Cancer Research UK Dacarbazine is a chemotherapy drug. It is used to treat melanoma, soft tissue sarcoma and Hodgkin lymphoma. Find out how you have it, possible sode effects and... cancer information dacarbazine dtic research uk https://adisinsight.springer.com/drugsafety/803928260?error=cookies_not_supported&code=82e67f5a-e71a-4e2d-a344-d1e541fdd6a4 Brentuximab vedotin/Dacarbazine/Vinblastine - AdisInsight A 48-year-old man with dyskeratosis congenita and stage IIA bulky classical Hodgkin lymphoma received a modified regimen including brentuximab vedotin, brentuximab vedotin dacarbazine vinblastine adisinsight